ライフサイエンスコーパス: donor leukocyte infusion

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 xicity comparable to that of matched-sibling donor leukocyte infusion.

2 recipients treated with DNA vaccination and donor leukocyte infusion.

3 mmarizes recent data on the use of unrelated-donor leukocyte infusion.

4 cutaneous graft-versus-host disease, without donor leukocyte infusion.

5 lapse after allogeneic transplantation using donor leukocyte infusions.

6 Donor leukocyte infusions (1x10(7) /kg CD3+ T cells) wer

7 Extensive data are available on the use of donor leukocyte infusion after matched-sibling stem cell

8 but reports are remarkably few on the use of donor leukocyte infusion after unrelated-donor stem cell

9 Donor leukocyte infusions after allogeneic bone marrow t

10 eneic peripheral blood cell transplantation, donor leukocyte infusions, and unrelated bone marrow tra

11 Donor leukocyte infusion (DLI) can induce graft-versus-l

12 In mice, donor leukocyte infusion (DLI) given to established mixe

13 r role in another model involving delayed B6 donor leukocyte infusion (DLI) to established mixed allo

14 A disease response to donor leukocyte infusion (DLI) was seen in 10 of 14 pati

15 ents achieved complete donor chimerism after donor leukocyte infusion (DLI).

16 l transplantation (alloHSCT) can be cured by donor leukocyte infusion (DLI); however, the cellular me

17 The efficacy and toxicity of donor leukocyte infusions (DLI) after unrelated donor bo

18 Therapy of recurrent disease with donor leukocyte infusions (DLI) has been proven to be ef

19 Donor leukocyte infusions (DLI) in the allogeneic hemato

20 Adoptive immunotherapy with donor leukocyte infusions (DLI) results in complete remi

21 effect has been provided by the efficacy of donor leukocyte infusions (DLI).

22 y alone, second myeloablative transplant, or donor leukocyte infusions (DLIs) alone is unusual.

23 We evaluated HLA-compatible donor leukocyte infusions (DLIs) and HLA-compatible or H

24 llowing bone marrow transplantation, delayed donor leukocyte infusions (DLIs) can induce graft-versus

25 Histocompatible allogeneic donor leukocyte infusions (DLIs) were administered as pr

26 together with the known antitumor effects of donor leukocyte infusions (DLIs), led to the design of t

27 In vitro analysis of splenocytes from donor leukocyte infusion donor mice demonstrated that im

28 Several case studies suggest that unrelated-donor leukocyte infusion effectively induces direct graf

29 ive allogeneic stem cell transplantation and donor leukocyte infusion for the induction of graft vers

30 In this murine system, donor leukocyte infusion from a donor immunized with the

31 Donor leukocyte infusion further enhances tumor-free sur

32 nsplantation has led to the use of unrelated-donor leukocyte infusion in many patients.

33 There is a paucity of data on unrelated-donor leukocyte infusion in this setting.

34 But the role for unrelated-donor leukocyte infusion is not well established.

35 Expression of MHC class I on donor leukocyte infusions is important for overcoming re

36 Donor leukocyte infusions provide direct and potent graf

37 d transplant and three of three who received donor leukocyte infusions) remain alive.

38 The dramatic success of donor leukocyte infusion to treat relapse after matched-

39 The effects of posttransplant donor leukocyte infusions to treat or prevent cytomegalo

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。